These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38787530)

  • 1. Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
    Nguyen CB; Reimers MA; Perera C; Abida W; Chou J; Feng FY; Antonarakis ES; McKay RR; Pachynski RK; Zhang J; Reichert ZR; Palmbos PL; Caram MEV; Vaishampayan UN; Heath EI; Hopkins AC; Cieslik MP; Wu YM; Robinson DR; Baladandayuthapani V; Chinnaiyan AM; Alva AS
    Clin Cancer Res; 2024 Aug; 30(15):3200-3210. PubMed ID: 38787530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
    Fizazi K; Retz M; Petrylak DP; Goh JC; Perez-Gracia J; Lacombe L; Zschäbitz S; Burotto M; Mahammedi H; Gravis G; Bastos DA; McCune SL; Vázquez Limón JC; Kwan EM; Castellano D; Fléchon A; Saad F; Grimm MO; Shaffer DR; Armstrong AJ; Bhagavatheeswaran P; Amin NP; Ünsal-Kaçmaz K; Wang X; Li J; Loehr A; Pachynski RK
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35977756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
    Shenderov E; Boudadi K; Fu W; Wang H; Sullivan R; Jordan A; Dowling D; Harb R; Schonhoft J; Jendrisak A; Carducci MA; Eisenberger MA; Eshleman JR; Luo J; Drake CG; Pardoll DM; Antonarakis ES
    Prostate; 2021 May; 81(6):326-338. PubMed ID: 33636027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
    J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.
    Fizazi K; González Mella P; Castellano D; Minatta JN; Rezazadeh Kalebasty A; Shaffer D; Vázquez Limón JC; Sánchez López HM; Armstrong AJ; Horvath L; Bastos DA; Amin NP; Li J; Unsal-Kacmaz K; Retz M; Saad F; Petrylak DP; Pachynski RK
    Eur J Cancer; 2022 Jan; 160():61-71. PubMed ID: 34802864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
    Sharma P; Pachynski RK; Narayan V; Fléchon A; Gravis G; Galsky MD; Mahammedi H; Patnaik A; Subudhi SK; Ciprotti M; Simsek B; Saci A; Hu Y; Han GC; Fizazi K
    Cancer Cell; 2020 Oct; 38(4):489-499.e3. PubMed ID: 32916128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
    J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.
    van Wilpe S; Kloots ISH; Slootbeek PHJ; den Brok M; Westdorp H; Franken MD; Coskunturk M; Osinga T; Bloemendal H; Adema G; Smeenk RJ; Nagarajah J; van Ipenburg J; Kroeze LI; Ligtenberg MJL; Schalken J; Gerritsen WR; Mehra N
    Ann Oncol; 2024 Dec; 35(12):1126-1137. PubMed ID: 39293514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort.
    Patel SP; Othus M; Chae YK; Huynh T; Tan B; Kuzel T; McLeod C; Lopez G; Chen HX; Sharon E; Streicher H; Ryan CW; Blanke C; Kurzrock R
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39067873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
    Markowski MC; Taplin ME; Aggarwal R; Sena LA; Wang H; Qi H; Lalji A; Sinibaldi V; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Sanin DE; Yegnasubramanian S; Gomes-Alexandre C; Ozbek B; Jones T; De Marzo AM; Denmeade SR; Antonarakis ES
    Nat Commun; 2024 Jan; 15(1):14. PubMed ID: 38167882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
    Subudhi SK; Siddiqui BA; Aparicio AM; Yadav SS; Basu S; Chen H; Jindal S; Tidwell RSS; Varma A; Logothetis CJ; Allison JP; Corn PG; Sharma P
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
    Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
    JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
    Oaknin A; Moore K; Meyer T; López-Picazo González J; Devriese LA; Amin A; Lao CD; Boni V; Sharfman WH; Park JC; Tahara M; Topalian SL; Magallanes M; Molina Alavez A; Khan TA; Copigneaux C; Lee M; Garnett-Benson C; Wang X; Naumann RW
    Lancet Oncol; 2024 May; 25(5):588-602. PubMed ID: 38608691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
    Patel SP; Guadarrama E; Chae YK; Dennis MJ; Powers BC; Liao CY; Ferri WA; George TJ; Sharon E; Ryan CW; Othus M; Lopez G; Blanke CD; Kurzrock R
    Cancer; 2024 Sep; 130(17):2918-2927. PubMed ID: 38358334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
    Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
    Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised phase II trial of stereotactic body radiotherapy in combination with
    Spindler NJ; Persson GF; Theile S; Nielsen DL; Høgdall EV; Al-Farra G; Hendel HW; Lorentzen T; Svane IM; Lindberg H; Eefsen RL
    BMJ Open; 2023 Jan; 13(1):e063500. PubMed ID: 36717150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
    Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.